SERPLULIMAB TRAS CONSEGUIR LA APROBACIÓN EN PRIMERA LÍNEA SMALL CELL LUNG CANCER EXTENSIVE-STAGE ... AHORA SE POSICIONA COMO POSIBLE TRATAMIENTO PARA SEGUNDA LINEA .... RESULTADOS EN EL MUNDO REAL : PACIENTES TRATADOS EN SEGUNDA LÍNEA CON SERPLULIMAB ( INMUNOTERAPIA ) CONSIGUEN MEJORAR LA PFS Y LA OVERALL SURVIVAL .

 

INVESTIGACIÓN EN EL MUNDO REAL DE LA INMUNOQUIMIOTERAPIA EN EL SMALL CELL LUNG CANCER EXTENSIVE-STAGE  :

 Oportunidades Para Enfoques de SEGUNDA LÍNEA .

LA INMUNOQUIMIOTERAPIA BASADA EN SERPLULIMAB, DE SEGUNDA LÍNEA , MUESTRA UNA PROMETEDORA ACTIVIDAD ANTITUMORAL Y BENEFICIOS EN LA SUPERVIVENCIA DEL  SMALL CELL LUNG CANCER , INDEPENDIENTEMENTE DE LA EXPOSICIÓN PREVIA A INMUNOTERAPIA .

Results :

 The Median Follow-Up Duration Was 13.7 Months .

 The OS Was 12.00 Months (95% CI: 6.87-Not Reached), and The Median PFS Was 4.07 Months ( 95% CI: 3.07–7.17 ), With An Objective Response Rate of 20.51% .

Patients Who Underwent Immunotherapy Re-Challenge Showed Numerically Higher Median OS ( 12.77 vs. 9.17 Months ) and PFS ( 5.93 vs. 3.87 Months ) Than Those Without Prior Immunotherapy .

Patients With An Objective Response to FRONT-LINE THERAPY Exhibited a Trend Toward Improved Median OS ( Not Reached vs. 6.47 Months ) and PFS ( 5.93 vs. 3.17 Months ) .

Cox Analysis Identified ECOG PS of 2, Elevated LDH, ProGrp, and NSE, and Liver Metastasis Were Associated With Worse OS .

The Most Common Adverse Events were Thrombocytopenia, Elevated ALT, and Hypothyroidism, with a Manageable Safety Profile .